Drug Trial Radar · NCT00567411
Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty
Last checked: Nov 19, 2026Latest source record: Dec 5, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
43
Planned (sponsor's estimate)
Start
Aug 2006
Primary completion
Not stated
Study completion Jun 2009
Sponsor
- Lead sponsor
- Walter Reed Army Medical CenterFederal agency
- Sponsor type
- Federal agency
- First posted
- Dec 5, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the safety and efficacy of two drops used to lower eye pressure when given prior to a glaucoma laser procedure.
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
brimonidine 0.1%Drug
1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
Apraclonidine 0.5%Drug
1 drop applied 1 hour prior to SLT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Postoperative IOPTime frame: 1 hour and 1 week post surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Walter Reed Army Medical Center
Washington D.C., District of Columbia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.